Ying Su

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu et al. · Cancer Cell · 2019 · 277 citations

Medicine, Oncology, Pharmacology +17

Colon cancer diagnosis and staging classification based on machine learning and bioinformatics analysis

Ying Su, Xuecong Tian, Rui Gao et al. · Computers in Biology and Medicine · 2022 · 183 citations

Medicine, Bioinformatics, Oncology +16

Lung Nodule Detection based on Faster R-CNN Framework

Ying Su, Dan Li · Computer Methods and Programs in Biomedicine · 2020 · 168 citations

Medicine, Radiology, Biomedical Imaging +10

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2022 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Filip Jankú, Albiruni R. Abdul Razak, Ping Chi et al. · Journal of Clinical Oncology · 2020 · 89 citations · Full text

Medicine, Oncology, Pharmacology +17